Doctor's Bio
Dr. David R. Goldsmith is a board-certified psychiatrist who focuses on the treatment of psychotic disorders and studies the role of the immune system in persistent symptoms of schizophrenia. More specifically, he is interested in how inflammation targets the brain, leading to motivational deficits and negative symptoms of schizophrenia. He is the co-director of the PSTAR (Persistent Symptoms: Treatment, Assessment, and Recovery) Clinic at Grady Memorial Hospital, which focuses on the treatment of individuals with psychosis, with a specific emphasis on using clozapine and other pharmacologic/psychosocial interventions for persistent symptoms. In addition to his work in the PSTAR Clinic, Dr. Goldsmith is on the faculty of the Emory Behavioral Immunology Program and is the Associate Program Director for the Emory Psychiatry Residency Research Track. Dr. Goldsmith completed his undergraduate work at the University of Maryland and received two National Institute of Mental Health Training Awards before receiving his MD from the Emory University School of Medicine. Dr. Goldsmith completed his psychiatry residency training at Emory University School of Medicine where he was on the residency research track.
Board Certifications
American Board of Psychiatry and Neurology
Affiliations
Emory
Education & Training
- Medical School: Emory University School of Medicine
- Residency: Emory University School of Medicine
Locations and Directions
Grady Memorial Hospital
Phone: (404) 616-1000
Location:
80 Jesse Hill Jr Drive SE
Atlanta, GA 30303
Publications
- Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.
Varghese JS, Goldsmith DR, Cotes RO, Ravikumar V, Ali MK, Pasquel FJ
International journal of obesity (2005). 2025;
PMID: 40817129 - The moderating role of lifetime social engagement on the relationship between C-reactive protein and negative symptoms among young adults at clinical high risk for psychosis.
Goldsmith DR, Yuan QE, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Carrión RE, Keshavan M, Mathalon DH, Perkins DO, Stone WS, Tsuang MT, Woods SW, Walker EF, Ku BS
Brain, behavior, and immunity. 2025;
PMID: 40730261 - Inflammation is associated with avolition and reduced resting state functional connectivity in corticostriatal reward circuitry in patients with schizophrenia.
Goldsmith DR, Ning CS, Strauss GP, Gross RE, Cooper JA, Wommack EC, Haroon E, Felger JC, Walker EF, Treadway MT, Miller AH
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2025;
PMID: 40274974 - Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.
de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer JM, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C
Journal of clinical psychopharmacology. ;45(3):197-218.
PMID: 40198784 - Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes.
de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer J, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C
Journal of clinical psychopharmacology. ;45(3):179-196.
PMID: 40198781 - Lipids and C-reactive protein predict anhedonia and reward circuit functional connectivity responses to anti-cytokine and dopaminergic therapies in patients with depression.
Singh A, Bekhbat M, Goldsmith DR, Le NA, Wommack EC, Li Z, Haroon E, Felger JC
Comprehensive psychoneuroendocrinology. 2025;
PMID: 39981264 - Sustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation.
Bekhbat M, Li Z, Dunlop BW, Treadway MT, Mehta ND, Revill KP, Lucido MJ, Hong C, Ashchi A, Wommack EC, Goldsmith DR, Haroon E, Miller AH, Felger JC
Brain, behavior, and immunity. 2025;
PMID: 39694342 - Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis.
Cohen S, Goldsmith DR, Ning CS, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Keshavan M, Mathalon DH, Perkins DO, Seidman LJ, Stone WS, Tsuang MT, Woods SW, Walker EF, Miller BJ
Psychiatry research. 2024;
PMID: 39197223 - The psychoneuroimmunology of Psychosis: Peeking past the clouds of Heterogeneity: Editorial.
Upthegrove R, Goldsmith DR
Brain, behavior, and immunity. 2024;
PMID: 38670242 - Immune and oxidative stress biomarkers in pediatric psychosis and psychosis-risk: Meta-analyses and systematic review.
Taylor JH, Bermudez-Gomez J, Zhou M, Gómez O, Ganz-Leary C, Palacios-Ordonez C, Huque ZM, Barzilay R, Goldsmith DR, Gur RE
Brain, behavior, and immunity. 2024;
PMID: 38141839
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.